Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 626 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib MOST POPULAR No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in... August 19, 2025 FDA Approves Trifluridine and Tipiracil with Bevacizumab for Previously Treated Metastatic... August 18, 2023 FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour April 4, 2025 EMA Recommends Extension of Therapeutic Indications for Encorafenib and Binimetinib August 23, 2024 Load more HOT NEWS Cancer in My Community: Accessing Care Through the Public Health System... Poorer Survival in Obese Colorectal Cancer Patients Possibly Linked to Lower... Risk of Distant Recurrence of ER-Positive Breast Cancer in Premenopausal Women... Many Patients with NSCLC Show Targetable Alterations in the PI3K Pathway
